Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Gastrointestinal 1CNS 1

Conditions

Neoplasms 1Leukemia, Myeloid, Acute 1Glioma 1Cholangiocarcinoma 1

Interventions

Specimen Handling 189Magnetic Resonance Spectroscopy 150pembrolizumab 147Carboplatin 110Biopsy 106Cyclophosphamide 92Cisplatin 85Paclitaxel 76Bevacizumab 68Gemcitabine 67Nivolumab 59fludarabine 56Fluorouracil 52Radiotherapy 49Capecitabine 49Pemetrexed 45Dexamethasone 45Oxaliplatin 44Rituximab 43Leucovorin 43atezolizumab 42Docetaxel 41venetoclax 39Doxorubicin 39durvalumab 37Temozolomide 32Standard of Care 32Radiation 32Prednisone 32Cetuximab 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Cytochrome P-450 CYP2C8 × 30 days × Clear all
NCT07486713 2026-06-05

Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

Rigel Pharmaceuticals

Phase 4 Recruiting
16 enrolled
CNSGastrointestinalOther hematologic neoplasm

Glioma, Neoplasms, Leukemia, Myeloid, Acute, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡